vs
Cytek Biosciences, Inc.（CTKB）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
Cytek Biosciences, Inc.的季度营收约是STANDARD BIOTOOLS INC.的19.3倍（$62.1M vs $3.2M）。STANDARD BIOTOOLS INC.净利率更高（598.5% vs -70.9%，领先669.4%）。STANDARD BIOTOOLS INC.同比增速更快（262.0% vs 8.1%）。STANDARD BIOTOOLS INC.自由现金流更多（$-1.7M vs $-1.8M）。过去两年Cytek Biosciences, Inc.的营收复合增速更高（17.7% vs -73.4%）
Cytek Biosciences主营高性能流式细胞分析系统、配套试剂及分析软件的研发、生产与商业化，产品服务覆盖生命科学研究、临床诊断、生物制药开发等领域，客户遍及全球多个主要地区。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
CTKB vs LAB — 直观对比
营收规模更大
CTKB
是对方的19.3倍
$3.2M
营收增速更快
LAB
高出253.9%
8.1%
净利率更高
LAB
高出669.4%
-70.9%
自由现金流更多
LAB
多$106.0K
$-1.8M
两年增速更快
CTKB
近两年复合增速
-73.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $62.1M | $3.2M |
| 净利润 | $-44.1M | $19.3M |
| 毛利率 | 52.9% | 83.5% |
| 营业利润率 | -9.0% | -578.6% |
| 净利率 | -70.9% | 598.5% |
| 营收同比 | 8.1% | 262.0% |
| 净利润同比 | -557.1% | 156.6% |
| 每股收益（稀释后） | — | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTKBLAB
| Q4 25 | $62.1M | $3.2M | ||
| Q3 25 | $52.3M | $19.6M | ||
| Q2 25 | $45.6M | $21.8M | ||
| Q1 25 | $41.5M | $40.8M | ||
| Q4 24 | $57.5M | $890.0K | ||
| Q3 24 | $51.5M | $22.1M | ||
| Q2 24 | $46.6M | $22.5M | ||
| Q1 24 | $44.9M | $45.5M |
净利润CTKBLAB
| Q4 25 | $-44.1M | $19.3M | ||
| Q3 25 | $-5.5M | $-34.7M | ||
| Q2 25 | $-5.6M | $-33.5M | ||
| Q1 25 | $-11.4M | $-26.0M | ||
| Q4 24 | $9.6M | $-34.1M | ||
| Q3 24 | $941.0K | $-26.9M | ||
| Q2 24 | $-10.4M | $-45.7M | ||
| Q1 24 | $-6.2M | $-32.2M |
毛利率CTKBLAB
| Q4 25 | 52.9% | 83.5% | ||
| Q3 25 | 52.7% | 48.5% | ||
| Q2 25 | 52.3% | 48.8% | ||
| Q1 25 | 48.6% | 48.4% | ||
| Q4 24 | 58.5% | -202.8% | ||
| Q3 24 | 56.3% | 54.9% | ||
| Q2 24 | 54.6% | 46.1% | ||
| Q1 24 | 51.3% | 53.1% |
营业利润率CTKBLAB
| Q4 25 | -9.0% | -578.6% | ||
| Q3 25 | -17.6% | -168.5% | ||
| Q2 25 | -23.3% | -118.1% | ||
| Q1 25 | -36.1% | -80.8% | ||
| Q4 24 | 5.2% | -1162.1% | ||
| Q3 24 | -8.2% | -120.9% | ||
| Q2 24 | -18.3% | -134.5% | ||
| Q1 24 | -23.9% | -132.2% |
净利率CTKBLAB
| Q4 25 | -70.9% | 598.5% | ||
| Q3 25 | -10.5% | -177.4% | ||
| Q2 25 | -12.2% | -153.7% | ||
| Q1 25 | -27.5% | -63.8% | ||
| Q4 24 | 16.8% | -3828.3% | ||
| Q3 24 | 1.8% | -122.0% | ||
| Q2 24 | -22.4% | -203.3% | ||
| Q1 24 | -13.8% | -70.6% |
每股收益（稀释后）CTKBLAB
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 25 | — | $-0.07 | ||
| Q4 24 | — | $-0.06 | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $-0.12 | ||
| Q1 24 | — | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.9M | $120.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $341.7M | $424.3M |
| 总资产 | $461.5M | $567.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTKBLAB
| Q4 25 | $90.9M | $120.9M | ||
| Q3 25 | $93.3M | $129.4M | ||
| Q2 25 | $75.5M | $158.6M | ||
| Q1 25 | $95.3M | $150.9M | ||
| Q4 24 | $98.7M | $166.7M | ||
| Q3 24 | $162.3M | $210.6M | ||
| Q2 24 | $177.9M | $269.8M | ||
| Q1 24 | $168.8M | $287.1M |
总债务CTKBLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $299.0K | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益CTKBLAB
| Q4 25 | $341.7M | $424.3M | ||
| Q3 25 | $378.6M | $399.7M | ||
| Q2 25 | $377.6M | $424.5M | ||
| Q1 25 | $379.6M | $454.6M | ||
| Q4 24 | $395.7M | $471.7M | ||
| Q3 24 | $385.5M | $489.3M | ||
| Q2 24 | $389.1M | $510.3M | ||
| Q1 24 | $392.6M | $577.3M |
总资产CTKBLAB
| Q4 25 | $461.5M | $567.8M | ||
| Q3 25 | $494.9M | $539.6M | ||
| Q2 25 | $493.3M | $557.0M | ||
| Q1 25 | $482.6M | $579.6M | ||
| Q4 24 | $499.5M | $612.3M | ||
| Q3 24 | $491.2M | $681.5M | ||
| Q2 24 | $483.7M | $708.7M | ||
| Q1 24 | $492.1M | $777.7M |
负债/权益比CTKBLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-771.0K | $-1.2M |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | $-1.7M |
| 自由现金流率自由现金流/营收 | -2.9% | -51.7% |
| 资本支出强度资本支出/营收 | 1.6% | 14.8% |
| 现金转化率经营现金流/净利润 | — | -0.06× |
| 过去12个月自由现金流最近4个季度 | $-8.8M | $-82.6M |
8季度趋势，按日历期对齐
经营现金流CTKBLAB
| Q4 25 | $-771.0K | $-1.2M | ||
| Q3 25 | $-3.9M | $-22.2M | ||
| Q2 25 | $108.0K | $-20.7M | ||
| Q1 25 | $-125.0K | $-30.3M | ||
| Q4 24 | $2.0M | $-14.1M | ||
| Q3 24 | $13.2M | $-27.9M | ||
| Q2 24 | $6.2M | $-39.0M | ||
| Q1 24 | $4.0M | $-62.5M |
自由现金流CTKBLAB
| Q4 25 | $-1.8M | $-1.7M | ||
| Q3 25 | $-4.6M | $-23.1M | ||
| Q2 25 | $-1.5M | $-22.6M | ||
| Q1 25 | $-974.0K | $-35.3M | ||
| Q4 24 | $1.1M | $-17.4M | ||
| Q3 24 | $12.2M | $-30.1M | ||
| Q2 24 | $5.2M | $-41.0M | ||
| Q1 24 | $3.4M | $-63.3M |
自由现金流率CTKBLAB
| Q4 25 | -2.9% | -51.7% | ||
| Q3 25 | -8.7% | -118.1% | ||
| Q2 25 | -3.2% | -103.6% | ||
| Q1 25 | -2.3% | -86.6% | ||
| Q4 24 | 1.9% | -1959.7% | ||
| Q3 24 | 23.7% | -136.4% | ||
| Q2 24 | 11.0% | -182.2% | ||
| Q1 24 | 7.6% | -138.9% |
资本支出强度CTKBLAB
| Q4 25 | 1.6% | 14.8% | ||
| Q3 25 | 1.3% | 4.5% | ||
| Q2 25 | 3.5% | 8.7% | ||
| Q1 25 | 2.0% | 12.4% | ||
| Q4 24 | 1.6% | 380.0% | ||
| Q3 24 | 2.0% | 10.2% | ||
| Q2 24 | 2.3% | 8.6% | ||
| Q1 24 | 1.3% | 1.7% |
现金转化率CTKBLAB
| Q4 25 | — | -0.06× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
LAB
暂无分部数据
